Press release summary
Clear Labs and Pillar Biosciences said Nov. 10 that they are expanding their collaboration to automate two research-use-only hematologic oncology panels on the Clear Dx next-generation sequencing platform. The companies plan to support Pillar’s oncoReveal Myeloid v2 Panel and oncoReveal Essential MPN Panel, with availability expected in early 2027.
Both panels use Pillar’s single-tube SLIMamp target-enrichment chemistry. Clear Dx will automate library preparation and sequencing setup, while Pillar’s PiVAT software will support data analysis. The companies said the workflow is intended to reduce manual pipetting and operator variability and to give laboratories a common automation platform for myeloid, myeloproliferative neoplasm, solid-tumor, liquid-biopsy and fusion-detection research. Clear Dx can also connect with secondary and tertiary bioinformatics systems for downstream interpretation and reporting.
Why it matters to laboratory readers
Automating targeted hematology NGS may help laboratories bring selected research workflows in-house instead of relying on send-out testing. Before adopting the system, laboratories should assess assay coverage, sample requirements, sequencing capacity, software interoperability, validation strategy and staffing. The products remain for research use only, and early-2027 availability is a company projection rather than a current commercial release.
Original release: Pillar Biosciences’ Nov. 10 announcement.
Leave a Reply